Table 2.
mRNA vs. protein |
D n = 11 |
M n = 13 |
All samples n = 24 |
---|---|---|---|
CYP1A2 | 0.845** | 0.775** | 0.744*** |
CYP2B6 | 0.773** | 0.593 | 0.790*** |
CYP2C8 | 0.909*** | 0.786** | 0.790*** |
CYP2C9 | 0.764** | 0.802*** | 0.381 |
CY2C19 | 0.601 | 0.884*** | 0.763*** |
CYP2D6a | 0.664* | 0.525 | 0.493* |
CYP2E1 | − 0.036 | 0.258 | 0.138 |
CYP3A4 | 0.845** | 0.780** | 0.851*** |
CYP3A5 | 0.691* | 0.676* | 0.744*** |
UGT1A1 | 0.609* | 0.626* | 0.722*** |
UGT1A3 | 0.236 | 0.527 | 0.430* |
UGT2B7 | 0.782** | 0.670* | 0.799*** |
UGT2B15 | 0.355 | 0.813*** | 0.492* |
Spearman coefficient values are given
M non-tumorous liver samples from patients with metastatic colon cancer, D liver samples from organ donors
*p < 0.05
**p < 0.01
***p < 0.001
aPatient deficient for CYP2D6 (*4/*4 genotype) was excluded from analysis